Purissima and Open Book Extracts enter partnership to achieve commercial scale production of minor cannabinoids

As part of the collaboration, Purissima will be the first company to achieve commercial scale production of minor cannabinoids using its proprietary algae-based fermentation platform.

Purissima (San Francisco, CA), a biotechnology health and wellness company, has announced an exclusive, multi-year processing and distribution partnership with Open Book Extracts (Roxboro, NC), a total solution provider for high quality cannabinoid ingredients. As part of the collaboration, Purissima will be the first company to achieve commercial scale production of minor cannabinoids using its proprietary algae-based fermentation platform. With production kicking off this month, the compounds are proposed to be available to manufacture and be sold to consumer brands before Fall of 2022.

"This exclusive partnership validates Purissima's capability to lead the industry forward in unprecedented research, fermentation scalability, and heightened minor cannabinoid access by consumers," said Robert Evans, Purissima co-founder and chief business and strategy officer, in a press release. "The partnership with Open Book Extracts will allow our sustainably produced, safe and therapeutic compounds to create a new landscape of cannabinoid-infused products for companies and consumers alike."

"Purissima's multi-patented technology has proven that bioengineering plant-based ingredients and medicinal compounds, such as in the case of minor cannabinoids, is indeed a reality and will provide unparalleled development and amplification of rare and hard to find compounds,” stated George Rudenko, co-founder, chief executive, and chief technology officer of Purissima. “Through the commercialization of our first compounds, Open Book Extracts and Purissima can jointly redefine how cannabinoids are sustainably sourced and their diverse health and wellness applications are realized at commercial scale."